|
1) |
Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol. 1989;142(4):1011-7. |
2) |
Lange PH, Ercole CJ, Lightner DJ, et al. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol. 1989;141(4):873-9. |
3) |
Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage , and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277(18):1445-51. |
4) |
Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150(1):110-4. |
5) |
Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms(Partin Tables)for the new millennium. Urology. 2001;58(6):843-8. |
6) |
Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol. 2001;165(5):1562-8. |
7) |
Egawa S, Suyama K, Ohori M, et al. Early detection of prostate cancer. Results of a prostate specific antigen-based detection program in Japan. Cancer. 1995;76(3):463-72. |
8) |
Oesterling JE, Kumamoto Y, Tsukamoto T, et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men:lower values than for similarly aged white men. Br J Urol. 1995;75(3):347-53. |
9) |
Egawa S, Suyama K, Arai Y, et al. A study of pretreatment nomograms to predict pathological stage and biochemical recurrence after radical prostatectomy for clinically resectable prostate cancer in Japanese men. Jpn J Clin Oncol. 2001;31(2):74-81. |
10) |
Horiguchi A, Nakashima J, Horiguchi Y, et al. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer. Prostate. 2003;56(1):23-9. |
11) |
Zlotta AR, Remzi M, Snow PB, et al. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10ng./ml. or less. J Urol. 2003;169(5):1724-8. |
12) |
Matsui Y, Egawa S, Tsukayama C, et al. Artificial neural network analysis for predicting pathological stage of clinically localized prostate cancer in the Japanese population. Jpn J Clin Oncol. 2002;32(12):530-5. |